Reported 8 months ago
Boehringer Ingelheim announced a manufacturing and supply agreement with TaiGen Pharma for the first Taiwan-produced, developed, and exported ophthalmic drug 'Betamethasone Suspension Eye Drops 0.05%' (APP13007) in the US market, aiming to capture the $13 billion market for corticosteroids and corticosteroid combinations in ophthalmology. The drug was the first approved by the FDA for eye use in 15 years and will be produced in Taiwan for export to the US, bolstered by advanced nanoparticle formulation technology. The partnership highlights Taiwan's capabilities in pharmaceutical innovation and manufacturing.
Source: YAHOO